BCD Bioscience Overview
- Founded
-
2019
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series A3
- Latest Deal Amount
-
$12M
- Investors
-
8
BCD Bioscience General Information
Description
Developer of naturally-derived oligosaccharides designed for food, agriculture, and biopharmaceutical applications. The company uses proprietary technology to create novel oligosaccharides from natural products, with a focus on producing ingredients that beneficially modulate the microbiome and immune function, enabling clients to access novel prebiotics, synbiotics, and immunomodulatory therapies for human and animal health.
Contact Information
Website
www.bcdbio.com
Formerly Known As
Calyxo Biosystems
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
- 231 G Street
- Suite 24
- Davis, CA 95616
- United States
+1 (530) 000-0000
BCD Bioscience Timeline
BCD Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A3) | 11-Mar-2022 | $12M | 000.00 | 0000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A1) | 09-Nov-2020 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 1. Grant | 29-Oct-2019 | $316K | Completed | Startup |
BCD Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A1 | 6,544,863 | $0.000100 | 6% | $0.64 | $0.64 | 1x | $0.64 | 23.17% |
BCD Bioscience Executive Team (6)
BCD Bioscience Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carlito Lebrilla Ph.D | Self | Co-Founder & Board Member | 000 0000 |
| Danilo Massari | Seventure Partners | Board Member | 000 0000 |
| Oxana Kukhaneva | Seventure Partners | Board Member | 000 0000 |
| Steven Watkins Ph.D | BCD Bioscience | Chief Executive Officer & Board Member | 000 0000 |
BCD Bioscience Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BCD Bioscience Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Collaborative Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Skyviews Life Science | Corporation | Minority | 000 0000 | 000000 0 | |
| Acre Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Argonautic Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Doon Capital | Family Office | Minority | 000 0000 | 000000 0 |